Discontinuation report BYDUREON

Last updated on 2022-04-01 History
Report ID 153603
Drug Identification Number 02448610
Brand name BYDUREON
Common or Proper name exenatide for extended-release injectable suspension
Company Name ASTRAZENECA CANADA INC
Market Status CANCELLED POST MARKET
Active Ingredient(s) EXENATIDE
Strength(s) 2MG
Dosage form(s) KIT POWDER FOR SUSPENSION, EXTENDED-RELEASE
Route of administration SUBCUTANEOUS SUBCUTANEOUS
Packaging size 4 single dose pens
ATC code A10BJ
ATC description BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Reason for discontinuation Business reasons
Anticipated discontinuation date 2022-03-31
Actual discontinuation date 2022-03-31
Remaining supply date 2022-10-31
Discontinuation status Discontinued
Discontinuation decision reversal No
Information on remaining supply The remaining product supply will provide coverage for approximately 1 month from discontinuation date.
Company comments
Health Canada comments
Tier 3 Status No
Company contact information Please contact AstraZeneca Canada Medical Information for any specific questions at 1-800-668-6000 (EN) or 1-800-461-3787 (FR) or by email: medinfo.canada@astrazeneca.com.

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v1 2022-01-26 English Compare
v2 2022-01-26 English Compare
v3 2022-01-26 French Compare
v4 2022-01-28 English Compare
v5 2022-01-28 French Compare
v6 2022-04-01 English Compare

Showing 1 to 6 of 6